



10 Mei 2024  
10 May 2024  
P.U. (A) 125

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT  
GAZETTE*

PERINTAH RACUN  
(PINDAAN SENARAI RACUN) 2024

*POISONS (AMENDMENT  
OF POISONS LIST) ORDER 2024*

DISIARKAN OLEH/  
PUBLISHED BY  
JABATAN PEGUAM NEGARA/  
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2024

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

**Nama**

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) 2024**.

**Pindaan Jadual Pertama**

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

*(a)* dalam Senarai Racun—

- (i) dengan menggantikan butiran “Adenosine” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Adenosine	-	-	Medicinal preparations unless exempted	All preparations unless in Group C or exempted	-	(1) Raw cordyceps  (2) Product which is registered under the Control of Drugs and Cosmetics Regulations 1984 containing adenosine from natural resources  (3) Cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984  (4) Food

(5) Its analogues,  
homologues,  
compounds,  
intermediates,  
derivatives, esters,  
ethers, salts and  
other  
substances  
structurally  
derived”;

(ii) dalam senarai “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”—

(A) dengan menggantikan butiran “Ephedra, alkaloids of, including synthetic preparations” dengan butiran “Ephedra, alkaloids of”;

(B) dengan menggantikan butiran “Rauwolfia, alkaloids of, including synthetic preparations” dengan butiran “Rauwolfia, alkaloids of”; dan

(C) dengan menggantikan butiran “Vinca, alkaloids of; including synthetic preparations” dengan butiran “Vinca, alkaloids of”;

- (iii) dengan menggantikan butiran “Azelaic Acid” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Azelaic acid	-	All medicinal preparations unless in Group C	Medicinal preparations for external use	All preparations unless in Group B or Group C	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (iv) dengan menggantikan butiran “Boric acid and Sodium borate” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Boric acid and Sodium borate	-	-	All medicinal preparations unless exempted	Preparations other than medicinal preparations unless exempted	-	(1) Preparations containing not more than 5% of Boric acid, or 5% of Sodium borate, or 5% of a combination of Boric acid and Sodium borate  (2) Preparations ready for use as pesticides or fertilizers  (3) Its analogues, homologues, compounds, intermediates,

derivatives,  
esters, ethers,  
salts and other  
substances  
structurally  
derived”;

- (v) dengan menggantikan butiran “Botulinum toxin; natural or synthetic” dengan butiran “Botulinum toxin”;
- (vi) dengan menggantikan butiran “Chloroform” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Chloroform	Veterinary preparations for food- producing animals	-	Medicinal preparation unless in Group A or exempted	All preparation unless in Group A, Group C or exempted	-	(1) Strengths under 10% unless in Group A  (2) Its analogues, homologues, compounds,

intermediates,  
 derivatives, esters,  
 ethers, salts and  
 other substances  
 structurally  
 derived”;

- (vii) dengan menggantikan butiran “Corticotrophins, natural and synthetic” dengan butiran “Corticotrophins”;
- (viii) dengan menggantikan butiran “Ethylidene diacetate” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ethylidene diacetate	-	-	-	All preparations unless exempted	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other

substances  
structurally derived”;

- (ix) dengan menggantikan butiran “Gamma Butyrolactone” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Gamma Butyrolactone	-	-	-	-	All preparations (1) unless exempted	When used as food additive in food  (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (x) dengan menggantikan butiran “Hypothalamic Hormones and their synthetic analogues” dengan butiran “Hypothalamic Hormones and their analogues”;

- (xi) dengan menggantikan butiran “Iodine” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Iodine	-	-	All preparations for parenteral administration.	All preparations unless in Group C or exempted	-	(1) Preparations containing less than 2% of iodine unless in Group C
			All medicinal preparations containing 2% and above of iodine			(2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xii) dengan menggantikan butiran “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:	All preparations containing local anaesthetics unless in Group B, Group C or Group D	All preparations in pharmaceutical dosage forms unless in Group C	(1) All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use  (2) Suppositories, lozenges and pastilles  (3) Preparations in the form of cartridges for dental use containing 2% or	Preparations for laboratory use	-	Denatonium benzoate”;

less of local  
anaesthetic

- (xiii) dengan memasukkan selepas butiran “Methyprylone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methylthioninium chloride	-	All preparations for parenteral administration	-	-	-	All preparations unless in Group B”;

- (xiv) dalam senarai “Monoclonal antibody; includes the following:”—

- (A) dengan memasukkan selepas butiran “Alirocumab” butiran “Amivantamab”;
- (B) dengan memasukkan selepas butiran “Cetuximab” butiran “Cilgavimab”; dan
- (C) dengan memasukkan selepas butiran “Sotrovimab” butiran “Tixagevimab”;

- (xv) dengan menggantikan butiran “Nitrobenzene” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Nitrobenzene	-	-	-	All preparations containing 0.1% and over unless exempted	-	(1) Under 0.1%  (2) Under 1% in soap  (3) Under 5% in polishes  (4) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xvi) dengan menggantikan butiran "Nitrophenols, ortho, meta and para" dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Nitrophenols, ortho, meta and para	-	-	-	All preparations unless exempted	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xvii) dengan menggantikan butiran "Oxalic acid; metallic oxalates" dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Oxalic acid; metallic oxalates	-	-	-	All preparations unless exempted	-	(1) Laundry blue, polishes, cleaning powders or scouring products, containing the equivalent of not more than 10% of oxalic acid dihydrate

(2) Ink eradicators containing not more than 5% of oxalic acid

(3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xviii) dengan menggantikan butiran “Oxytocins; natural and synthetic” dengan butiran “Oxytocins”;

(xix) dengan menggantikan butiran “Phenolphthalein” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Phenolphthalein	-	-	All preparations for therapeutic use	-	All preparations unless in Group C or exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xx) dengan menggantikan butiran "Picric acid" dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Picric acid	-	-	-	All preparations unless exempted	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xxi) dengan menggantikan butiran "Piperazine unless stated elsewhere in the List" dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Piperazine unless stated elsewhere in the List	-	-	-	-	All preparations unless exempted	(1) Cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984  (2) Product which is registered under the Control of Drugs and Cosmetics Regulations 1984  (3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other

substances structurally  
derived”;

(xxii) dengan menggantikan butiran “Prostaglandins and its synthetic derivatives; their salts; their esters” dengan butiran “Prostaglandins and its derivatives; their salts; their esters”;

(xxiii) dengan memasukkan selepas butiran “Regorafenib” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Remdesivir	-	All preparations”;				

(xxiv) dengan memasukkan selepas butiran “Selexipag” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Selumetinib	-	All preparations";				

(xxv) dengan menggantikan butiran "Sex hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following:" dengan butiran "Sex Hormones-androgenic, oestrogenic and progestational, the following:";

(xxvi) dengan menggantikan butiran "Vasopressins, natural and synthetic" dengan butiran "Vasopressins"; dan

(xxvii) dengan memasukkan selepas butiran "Zoxazolamine; its salts" dan butir-butir yang berhubungan dengannya perenggan yang berikut:

"In the construction of this List, unless the contrary intention appears, a reference to a substance mentioned in the first column of this Schedule shall include a reference to that substance prepared either from natural sources or synthetically."; dan

(b) dalam Lampiran kepada Senarai Racun—

(i) dalam senarai "**Antihypertensives**:", dengan menggantikan butiran "Rauwolfia, alkaloids of, including synthetic preparations" dengan butiran "Rauwolfia, alkaloids of";

- (ii) dalam senarai “**Antineoplastic agents and Immunosuppressants:**”—
  - (A) dengan memasukkan selepas butiran “Aminoglutethimide” butiran “Amivantamab”;
  - (B) dengan memasukkan selepas butiran “Secukinumab” butiran “Selumetinib”; dan
  - (C) dengan menggantikan butiran “Vinca, alkaloids of, including synthetic preparations” dengan butiran “Vinca, alkaloids of”;
- (iii) dalam senarai “**Antiviral agents:**”—
  - (A) dengan memasukkan selepas butiran “Boceprevir” butiran “Cilgavimab”;
  - (B) dengan memasukkan selepas butiran “Regdanvimab” butiran “Remdesivir”; dan
  - (C) dengan memasukkan selepas butiran “Tenofovir” butiran “Tixagevimab”;
- (iv) dalam senarai “**Hormones:**”—
  - (A) dengan menggantikan butiran “Corticotrophins, natural and synthetic” dengan butiran “Corticotrophins”;

- (B) dengan menggantikan butiran “Hypothalamic Hormones and their synthetic analogues” dengan butiran “Hypothalamic Hormones and their analogues”;
  - (C) dengan menggantikan butiran “Oxytocins, natural and synthetic” dengan butiran “Oxytocins”;
  - (D) dengan menggantikan butiran “Sex Hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following:” dengan butiran “Sex Hormones-androgenic, oestrogenic and progestational, the following:”; dan
  - (E) dengan menggantikan butiran “Vasopressins, natural and synthetic” dengan butiran “Vasopressins”;
- (v) dalam senarai “**Sympathomimetic amines:**”, dengan menggantikan butiran “Ephedra, alkaloids of, including synthetic preparations” dengan butiran “Ephedra, alkaloids of”; dan
- (vi) dalam senarai “**Miscellaneous:**”—
- (A) dengan menggantikan butiran “Botulinum toxin; natural or synthetic” dengan butiran “Botulinum toxin”;
  - (B) dengan memasukkan selepas butiran “Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PICA)” butiran “Methylthioninium chloride”; dan

- (C) dengan menggantikan butiran “Prostaglandins and its synthetic derivatives; their salts; their esters” dengan butiran “Prostaglandins and its derivatives; their salts; their esters”.

Dibuat 25 April 2024  
[KKM.600-18/2/95; PN(PU2)172/JLD.20]

DATUK SERI DR. HAJI DZULKEFLY BIN AHMAD  
*Menteri Kesihatan*

## POISONS ACT 1952

## POISONS (AMENDMENT OF POISONS LIST) ORDER 2024

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

**Citation**

1. This order may be cited as the **Poisons (Amendment of Poisons List) Order 2024**.

**Amendment of First Schedule**

2. The Poisons Act 1952 is amended in the First Schedule—

(a) in the Poisons List—

- (i) by substituting for the item “Adenosine” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Adenosine	-	-	Medicinal preparations unless exempted	All preparations unless in Group C or exempted	-	(1) Raw cordyceps  (2) Product which is

registered under the  
Control of Drugs and  
Cosmetics  
Regulations 1984  
containing adenosine  
from natural  
resources

(3) Cosmetic which is  
notified under the  
Control of Drugs and  
Cosmetics  
Regulations 1984

(4) Food

(5) Its analogues,  
homologues,  
compounds,  
intermediates,  
derivatives, esters,

ethers, salts and  
other substances  
structurally derived”;

- (ii) in the list of “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”—
  - (A) by substituting for the item “Ephedra, alkaloids of, including synthetic preparations” the item “Ephedra, alkaloids of”;
  - (B) by substituting for the item “Rauwolfia, alkaloids of, including synthetic preparations” the item “Rauwolfia, alkaloids of”; and
  - (C) by substituting for the item “Vinca, alkaloids of; including synthetic preparations” the item “Vinca, alkaloids of”;
- (iii) by substituting for the item “Azelaic Acid” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Azelaic acid	-	All medicinal preparations unless in Group C	Medicinal preparations for external use	All preparations unless in Group B or Group C	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(iv) by substituting for the item "Boric acid and Sodium borate" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Boric acid and Sodium borate	-	-	All medicinal preparations unless exempted	Preparations other than medicinal preparations	-	(1) Preparations containing not more than 5% of Boric acid, or 5%

unless  
exempted

of Sodium borate,  
or 5% of a  
combination of  
Boric acid and  
Sodium borate

(2) Preparations  
ready for use as  
pesticides or  
fertilizers

(3) Its analogues,  
homologues,  
compounds,  
intermediates,  
derivatives,  
esters, ethers,  
salts and other  
substances  
structurally  
derived”;

- (v) by substituting for the item “Botulinum toxin; natural or synthetic” the item “Botulinum toxin”;
- (vi) by substituting for the item “Chloroform” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Chloroform	Veterinary preparations for food-producing animals	-	Medicinal preparation unless in Group A or exempted	All preparation unless in Group A, Group C or exempted	-	(1) Strengths under 10% unless in Group A  (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (vii) by substituting for the item “Corticotrophins natural and synthetic” the item “Corticotrophins”;

(viii) by substituting for the item “Ethylidene diacetate” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ethylidene diacetate	-	-	-	All preparations unless exempted	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(ix) by substituting for the item “Gamma Butyrolactone” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Gamma Butyrolactone	-	-	-	-	All preparations (1) unless exempted	When used as food additive in food

(2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(x) by substituting for the item “Hypothalamic Hormones and their synthetic analogues” the item “Hypothalamic Hormones and their analogues”;

(xi) by substituting for the item “Iodine” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Iodine	-	-	All preparations for parenteral administration.	All preparations unless in Group C or exempted	-	(1) Preparations containing less than 2% of iodine unless in Group C

All medicinal preparations containing 2% and above of iodine

(2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xii) by substituting for the item “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Local anaesthetics; the following: their salts; their homologues and	All preparations containing local anaesthetics unless in Group B,	All preparations in pharmaceutical dosage forms unless in Group C	(1) All preparations in pharmaceutical dosage form for topical use in the nose, eyes and	Preparations for laboratory use	-	Denatonium benzoate”;

analogues; their molecular compounds:	Group C or Group D	ears or external use
		(2) Suppositories, lozenges and pastilles
		(3) Preparations in the form of cartridges for dental use containing 2% or less of local anaesthetic

(xiii) by inserting after the item "Methypylone" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Methylthioninium chloride	-	All preparations for parenteral administration	-	-	-	All preparations unless in Group B";

(xiv) in the list of "Monoclonal antibody; includes the following:"—

(A) by inserting after the item "Alirocumab" the item "Amivantamab";

(B) by inserting after the item "Cetuximab" the item "Cilgavimab"; and

(C) by inserting after the item "Sotrovimab" the item "Tixagevimab";

(xv) by substituting for the item "Nitrobenzene" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Nitrobenzene	-	-	-	All preparations containing	-	(1) Under 0.1%  (2) Under 1% in soap

0.1% and over  
 unless  
 exempted

(3) Under 5% in polishes

(4) Its analogues, homologues,  
 compounds,  
 intermediates, derivatives,  
 esters, ethers, salts and  
 other substances  
 structurally derived”;

(xvi) by substituting for the item “Nitrophenols, ortho, meta and para” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nitrophenols, ortho, meta and para	-	-	-	All preparations unless exempted	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xvii) by substituting for the item “Oxalic acid; metallic oxalates” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Oxalic acid; metallic oxalates	-	-	-	All preparations unless exempted	-	(1) Laundry blue, polishes, cleaning powders or scouring products, containing the equivalent of not more than 10% of oxalic acid dehydrate  (2) Ink eradicators containing not more than 5% of oxalic acid  (3) Its analogues, homologues, compounds, intermediates,

derivatives, esters,  
ethers, salts and other  
substances  
structurally derived”;

(xviii) by substituting for the item “Oxytocins; natural and synthetic” the item “Oxytocins”;

(xix) by substituting for the item “Phenolphthalein” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Phenolphthalein	-	-	All preparations for therapeutic use	-	All preparations unless in Group C or exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xx) by substituting for the item “Picric acid” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Picric acid	-	-	-	All preparations unless exempted	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xxi) by substituting for the item "Piperazine unless stated elsewhere in the List" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Piperazine unless stated elsewhere in the List	-	-	-	-	All preparations unless exempted	(1) Cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984

(2) Product which is registered under the Control of Drugs and Cosmetics Regulations 1984

(3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxii) by substituting for the item “Prostaglandins and its synthetic derivatives; their salts; their esters” the item “Prostaglandins and its derivatives; their salts; their esters”;

(xxiii) by inserting after the item “Regorafenib” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Remdesivir	-	All preparations";				

(xxiv) by inserting after the item "Selexipag" and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Selumetinib	-	All preparations";				

(xxv) by substituting for the item "Sex hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following:" the item "Sex Hormones-androgenic, oestrogenic and progestational, the following:";

(xxvi) by substituting for the item "Vasopressins, natural and synthetic" the item "Vasopressins"; and

(xxvii) by inserting after the item "Zoxazolamine; its salts" and the particulars relating to it the following paragraph:

"In the construction of this List, unless the contrary intention appears, a reference to a substance mentioned in the first column of this Schedule shall include a reference to that substance prepared either from natural sources or synthetically."; and

- (b) in the Appendix to the Poisons List—
- (i) in the list of “**Antihypertensives:**”, by substituting for the item “Rauwolfia, alkaloids of, including synthetic preparations” the item “Rauwolfia, alkaloids of”;
- (ii) in the list of “**Antineoplastic agents and Immunosuppressants:**”—
- (A) by inserting after the item “Aminoglutethimide” the item “Amivantamab”;
- (B) by inserting after the item “Secukinumab” the item “Selumetinib”; and
- (C) by substituting for the item “Vinca, alkaloids of, including synthetic preparations” the item “Vinca, Alkaloids of”;
- (iii) in the list of “**Antiviral agents:**”—
- (A) by inserting after the item “Boceprevir” the item “Cilgavimab”;
- (B) by inserting after the item “Regdanvimab” the item “Remdesivir”; and
- (C) by inserting after the item “Tenofovir” the item “Tixagevimab”;

- (iv) in the list of "**Hormones:**"—
- (A) by substituting for the item "Corticotrophins natural and synthetic" the item "Corticotrophins";
  - (B) by substituting for the item "Hypothalamic Hormones and their synthetic analogues" the item "Hypothalamic Hormones and their analogues";
  - (C) by substituting for the item "Oxytocins; natural and synthetic" the item "Oxytocins";
  - (D) by substituting for the item "Sex Hormones-androgenic, oestrogenic and progestational, natural or synthetic, the following:" the item "Sex Hormones-androgenic, oestrogenic and progestational, the following:"; and
  - (E) by substituting for the item "Vasopressins, natural and synthetic" the item "Vasopressins";
- (v) in the list of "**Sympathomimetic amines:**", by substituting for the item "Ephedra, alkaloids of, including synthetic preparations" the item "Ephedra, alkaloids of"; and
- (vi) in the list of "**Miscellaneous:**"—
- (A) by substituting for the item "Botulinum toxin; natural or synthetic" the item "Botulinum toxin";

- (B) by inserting after the item “Methyl (2S)-2-{{1-(5-fluoropentyl)-1H-indole-3-carbonyl}amino}-3,3-dimethylbutanoate (5F-MDMB-PICA)” the item “Methylthioninium chloride”; and
- (C) by substituting for the item “Prostaglandins and its synthetic derivatives; their salts; their esters” the item “Prostaglandins and its derivatives; their salts; their esters”.

Made 25 April 2024

[KKM.600-18/2/95; PN(PU2)172/JLD.20]

DATUK SERI DR. HAJI DZULKEFLY BIN AHMAD  
*Minister of Health*